Results 191 to 200 of about 39,017 (214)

[Clopidogrel resistance: myth or reality].

Kardiologiia, 2008
The efficacy of clopidogrel, as an established anti-platelet agent for the acute coronary syndrome treatment and for the thrombotic complications prevention after percutaneous coronary angioplasty and coronary artery stenting has been supported by the evidence of several major randomized clinical trials.
V L, Serebrianyĭ, A I, Malinin, L M, Makarov   +2 more
openaire   +1 more source

Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial

Lancet, The, 2021
Bon-Kwon Koo, Jeehoon Kang, Han-Mo Yang
exaly  

Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction

Circulation, 2004
Michael Shechter, Ilan Goldenberg, Ilya Novikov   +2 more
exaly  

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial

Lancet, The, 2013
Johannes C Kelder, Marije M Vis
exaly  

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

Lancet, The, 2004
Hans-Christoph Diener, Claudio Cimminiello, László Csiba   +2 more
exaly  

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

Lancet, The, 2009
Gilles Montalescot, C Michael Gibson
exaly  

Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance

Circulation, 2004
Paul A Gurbel
exaly  

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

Lancet, The, 2009
Michelle L O'donoghue, Eugene Braunwald, Elliott M Antman   +2 more
exaly  

Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial

Lancet, The, 2020
Laura M Willemsen, Thomas O Bergmeijer, Clemens Von Birgelen C   +2 more
exaly  

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

Lancet, The, 2009
Jean-Philippe Collet, Jean-Sébastien Hulot, Eric Villard   +2 more
exaly